Valneva SE
World Trade Center Lyon, Tour Oxygène
10-12 boulevard Marius Vivier Merle
Lyon
69003
France
Tel: 33-4-78-76-61-01
Website: http://www.valneva.com/
About Valneva SE
Valneva is a fully integrated vaccine company that specializes in the development, manufacture and commercialization of innovative vaccines with a mission to protect people from infectious diseases through preventative medicine.LEADERSHIP:
CEO: Thomas Lingelbach
CFO: Reinhard Kandera
33 articles with Valneva SE
-
Valneva and Pfizer Complete Recruitment for Phase 2 Trial of Lyme Disease Vaccine Candidate
7/19/2021
Valneva SE, a specialty vaccine company focused on the development and commercialization of prophylactic vaccines for infectious diseases with significant unmet medical need, and Pfizer Inc., announced that they have completed recruitment for the Phase 2 trial, VLA15-221, of Lyme disease vaccine candidate, VLA15.
-
Valneva Strengthens Management Team; Appoints Vincent Dequenne as SVP Operations and Joshua Drumm as VP Investor Relations
7/6/2021
ValnevaSE, a specialty vaccine company focused on the development and commercialization of prophylactic vaccines for infectious diseases with significant unmet medical need, announced it has appointed Vincent Dequenne as Senior Vice President Operations and Joshua Drumm as Vice President Investor Relations.
-
Valneva to Host Symposium on COVID-19 and Chikungunya Vaccine Candidates at 31st European Congress of Clinical Microbiology & Infectious Diseases
7/5/2021
ValnevaSE announced it will host a virtual symposium titled, “Developing new vaccines to protect against infectious diseases at home and abroad” on July 9, 2021 at 14:15 CEST at the 31st European Congress of Clinical Microbiology & Infectious Diseases.
-
Valneva Continues Ongoing Discussions with the European Commission for Inactivated COVID-19 Vaccine Candidate
7/1/2021
Following a media article published yesterday, ValnevaSE, a specialty vaccine company focused on the development and commercialization of prophylactic vaccines for infectious diseases with significant unmet medical need, indicated it continues ongoing discussions with the European Commission regarding VLA2001, Valneva’s inactivated COVID-19 vaccine candidate.
-
Valneva Announces Successful Outcome of its AGM
6/23/2021
Valneva S E announced today that all the resolutions recommended by the Management Board were approved by the shareholders at its Annual General Meeting (AGM) held as a closed session at its registered office on June 23, 2021.
-
Valneva Completes Recruitment for Phase 3 Lot-to-Lot Consistency Trial of its Chikungunya Vaccine Candidate
6/10/2021
Valneva SE announced that it has completed recruitment for the clinical lot-to-lot consistency Phase 3 trial of its single-shot chikungunya vaccine candidate, VLA1553.
-
There were seven initial public offerings (IPOs) for biotech companies in the month of May. Here’s a look.
-
Valneva Reports Q1 2021 Financial Results and Business Update
5/20/2021
Valneva SE, a specialty vaccine company focused on the development and commercialization of prophylactic vaccines for infectious diseases with significant unmet medical need, reported today its first quarter financial results ending March 31, 2021.
-
Money on the Move: May 5 - 11
5/12/2021
Catch up on the investment news quickly with BioSpace's brief overview of the biotech companies hitting the Nasdaq and raking in fresh cash the past week. -
Valneva Announces Closing of $107.6 million Global Offering
5/11/2021
Valneva's ordinary shares are listed on Euronext Paris under the symbol “VLA” and its ADSs are listed on the Nasdaq Global Select Market under the symbol “VALN”.
-
Valneva Announces Full Exercise of Underwriters’ Option to Purchase Additional ADSs, Bringing Gross Proceeds of Global Offering to $107.6 Million
5/10/2021
Valneva SE announced that the underwriters of its global offering of an aggregate of 7,082,762 new ordinary shares, consisting of a public offering of 2,318,881 American Depositary Shares, each representing two ordinary shares, and a concurrent private placement of 2,445,000 ordinary shares in Europe and other countries outside of the United States, have exercised in full their option to purchase up to 1,062,414 additional new ordinary shares in the form of 531,207 ADSs.
-
With 2020 holding a record number of biotech IPOs, this year is lining up to come close. Three more Bay Area life science companies are just about ready to hit the Nasdaq, adding to the growing list for 2021.
-
Valneva Announces the Pricing of its Initial Public Offering on Nasdaq
5/6/2021
Saint-Herblain (France), May 6, 2021 – Valneva SE, a specialty vaccine company focused on the development and commercialization of prophylactic vaccines for infectious diseases with significant unmet medical need, announced today the pricing of its initial public offering on the Nasdaq Global Select Market by way of a capital increase of 7,082,762 new ordinary shares, consisting of a public offering of 2,318,881 American Depositary Shares (“ ADSs ”), each representing two ordinary shares (th
-
Positive Phase 1/2 Results for Valneva's Inactivated COVID-19 Vaccine Candidate Using Dynavax's CpG 1018™ Adjuvant
4/6/2021
VLA2001, an inactivated COVID-19 vaccine candidate with CpG 1018 adjuvant, was highly immunogenic and generally safe and well tolerated
-
Clinical Catch-Up: January 25-29
2/1/2021
It was a busy week for clinical trial news. Read on for more information. -
BioSpace Movers & Shakers, Jan. 15
1/15/2021
Biopharma and life sciences companies strengthen their leadership teams and boards with these Movers and Shakers. -
Biopharma and life sciences companies from across the globe provide updates on their pipelines and businesses.
-
Clinical Catch-Up: December 14-18
12/21/2020
Many companies appear to be getting their clinical trial news updated ahead of the holidays. Here’s a look. -
As we eagerly look ahead to 2021, BioSpace spoke to four biotechs hoping to seize this opportunity in the first wave of COVID-19 vaccines and therapies – or make an impact in the second.
-
It’s been a busy day so far for biopharma news and updates. Read on for more.